Literature DB >> 3024746

Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study.

G S Zubenko, J K Marquis, L Volicer, L K Direnfeld, P J Langlais, R A Nixon.   

Abstract

Mean levels of the two hydrolases angiotensin-converting enzyme (ACE) and acetylcholinesterase (AChE), the dopamine metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), and total protein concentration were examined in cerebrospinal fluid (CSF) samples from a group of patients with dementia of the Alzheimer's type, a group of comparably demented patients with Parkinson's disease, and a neurologically healthy elderly control group. Both pathological groups exhibited a significant decrease in the mean levels of ACE activity and DOPAC per milliliter and were distinguishable from one another based on mean CSH HVA levels. Unlike the Parkinson's disease group, whose mean concentration of HVA was lower than, but not significantly different from that of the control group, the mean HVA concentration of the Alzheimer's disease group was significantly elevated. In contrast, comparisons of the mean CSF AChE activity (expressed per milliliter or per milligram of protein) and CSF total protein concentration did not reveal significant differences for any of the groups. Independent of CSF protein concentration, ACE activity per milliliter exhibited a positive correlation with AChE activity per milliliter within the control and Parkinson's disease groups, whereas a statistically significant correlation for these CSF hydrolases was not observed within the Alzheimer's disease group. Thus, the CSF profiles for patients with mild dementias associated with Alzheimer's or Parkinson's disease differed by at least two neurochemical criteria. Based on the levels of ACE activity, DOPAC, and HVA per milliliter of CSF, two discriminant functions were derived and resulted in the correct classification of 71% of all subjects (n = 38) into Alzheimer's disease, Parkinson's disease, and neurologically healthy control groups.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3024746     DOI: 10.1016/0006-3223(86)90328-8

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  14 in total

1.  Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease.

Authors:  S Engelborghs; B Marescau; P P De Deyn
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

2.  ACE variants and association with brain Aβ levels in Alzheimer's disease.

Authors:  J Scott Miners; Zoë van Helmond; Merryn Raiker; Seth Love; Patrick G Kehoe
Journal:  Am J Transl Res       Date:  2010-10-15       Impact factor: 4.060

3.  Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies.

Authors:  David S Goldstein; Courtney Holmes; Yehonatan Sharabi
Journal:  Brain       Date:  2012-03-26       Impact factor: 13.501

Review 4.  Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.

Authors:  Alberto Lleó; Enrica Cavedo; Lucilla Parnetti; Hugo Vanderstichele; Sanna Kaisa Herukka; Niels Andreasen; Roberta Ghidoni; Piotr Lewczuk; Andreas Jeromin; Bengt Winblad; Magda Tsolaki; Barbara Mroczko; Pieter Jelle Visser; Isabel Santana; Per Svenningsson; Kaj Blennow; Dag Aarsland; José Luis Molinuevo; Henrik Zetterberg; Brit Mollenhauer
Journal:  Nat Rev Neurol       Date:  2014-12-16       Impact factor: 42.937

5.  Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes.

Authors:  Scott Miners; Emma Ashby; Shabnam Baig; Rachel Harrison; Hannah Tayler; Elizabeth Speedy; Jonathan A Prince; Seth Love; Patrick G Kehoe
Journal:  Am J Transl Res       Date:  2009-01-18       Impact factor: 4.060

6.  Acetylcholine synthesis in human CSF: implications for study of central cholinergic metabolism.

Authors:  S T DeKosky; S W Scheff; C G Hackney
Journal:  Neurochem Res       Date:  1989-02       Impact factor: 3.996

Review 7.  Angiotensin converting enzyme inhibitors as potential cognitive enhancing agents.

Authors:  A M Domeney
Journal:  J Psychiatry Neurosci       Date:  1994-01       Impact factor: 6.186

Review 8.  Monoaminergic neuropathology in Alzheimer's disease.

Authors:  Goran Šimić; Mirjana Babić Leko; Selina Wray; Charles R Harrington; Ivana Delalle; Nataša Jovanov-Milošević; Danira Bažadona; Luc Buée; Rohan de Silva; Giuseppe Di Giovanni; Claude M Wischik; Patrick R Hof
Journal:  Prog Neurobiol       Date:  2016-04-12       Impact factor: 11.685

Review 9.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

10.  Angiotensins and Alzheimer's disease: a bench to bedside overview.

Authors:  Patrick G Kehoe
Journal:  Alzheimers Res Ther       Date:  2009-07-09       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.